6CM
IOVA icon

683 Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

683 Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.26M Buy
+644,300
New +$2.06M 0.12% 100

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

683 Capital Management's IOVA Position: Q2 2025 in Review

683 Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 2,400,000 shares — an estimated $7.99M sold.

683 Capital Management first reported a position in IOVA in Q3 2017 and held it in 24 quarters. The position peaked at $26.7M in Q2 2021. 255 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • 683 Capital Management reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • 683 Capital Management sold 2,400,000 Iovance Biotherapeutics shares in Q2 2025, an estimated $7.99M.
  • 683 Capital Management first reported a position in Iovance Biotherapeutics in Q3 2017 and held it in 24 quarters.
  • 683 Capital Management's Iovance Biotherapeutics position peaked at $26.7M in Q2 2021.
  • 255 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on 683 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.